Provided are an oncolytic virus for treating brain tumors using a recombinant Newcastle disease virus into which a Newcastle disease virus (NDV) vector-based PTEN (phosphatase and tensin homolog) gene is inserted and a composition for treating brain tumors using the same which can be used for a therapeutic viral agent that can induce reduction of clinical symptoms or partial or complete remission through brain tumor cell death or brain tumor tissue reduction by expressing normal PTEN protein after being infected with brain tumor cells, as a recombinant Newcastle disease virus containing a human PTEN protein gene.

The present invention provides a therapy for treating loss of GABA-mediated pre-synaptic inhibition after spinal injury. The therapeutic regimen includes spinal segment-specific upregulation of GAD65 (glutamate decarboxylase) and VGAT (vesicular GABA transporter) to modulate chronic spasticity in patients after spinal traumatic or ischemic injury.

Infectious diseases can be transmitted to humans, or between humans and animals, by airborne viruses and bacteria, known as infectious aerosols. Current protective measures that individuals can take to avoid inhaling such aerosols are either marginally effective (personal face masks) or impractical (self-contained breathing apparatuses). Building ventilation systems employing high-efficiency filters to prevent distribution of such aerosols suffer from high energy costs and high filter replacement costs. The development of conventional, intramuscularly administered vaccines takes months or years to produce enough doses to protect a population from a rapidly spreading infectious disease. Airborne viruses and bacteria have been shown to be completely inactivated when exposed to non-thermal plasmas. Results indicate the potential for sub-lethal exposures of airborne pathogens could render them unable to spark an infection in a host, but still retain the necessary surface proteins to cause an immune response in the host.

The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the truncated L1 protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.

A method for preparing test solution for pathogen detection purpose, system, kit, detection primer and method are provided. The method of preparing a test solution includes lysing the sample to be tested with a lysis buffer to release the nucleic acids contained in the sample to obtain a lysis buffer containing nucleic acids and/or pathogen nucleic acids; extracting the lysis buffer containing nucleic acids through a nucleic acid extraction device to obtain an extract containing host nucleic acids and/or pathogen nucleic acids; preparing the test solution for pathogen detection purposes from the extract. A large volume of samples can be used in the present application and it greatly improves sensitivity and specificity of the assay.

Provided are an oncolytic virus for treating brain tumors using a recombinant Newcastle disease virus into which a Newcastle disease virus (NDV) vector-based PTEN (phosphatase and tensin homolog) gene is inserted and a composition for treating brain tumors using the same which can be used for a therapeutic viral agent that can induce reduction of clinical symptoms or partial or complete remission through brain tumor cell death or brain tumor tissue reduction by expressing normal PTEN protein after being infected with brain tumor cells, as a recombinant Newcastle disease virus containing a human PTEN protein gene.

Infectious diseases can be transmitted to humans, or between humans and animals, by airborne viruses and bacteria, known as infectious aerosols. Current protective measures that individuals can take to avoid inhaling such aerosols are either marginally effective (personal face masks) or impractical (self-contained breathing apparatuses). Building ventilation systems employing high-efficiency filters to prevent distribution of such aerosols suffer from high energy costs and high filter replacement costs. The development of conventional, intramuscularly administered vaccines takes months or years to produce enough doses to protect a population from a rapidly spreading infectious disease. Airborne viruses and bacteria have been shown to be completely inactivated when exposed to non-thermal plasmas. Results indicate the potential for sub-lethal exposures of airborne pathogens could render them unable to spark an infection in a host, but still retain the necessary surface proteins to cause an immune response in the host.

The present application discloses a recombinant Newcastle disease virus genome, a recombinant Newcastle disease virus rNDV-VEGF-Trap containing the genome and a preparation method therefor, a DNA molecule encoding the recombinant Newcastle disease virus genome, and a use of the genome and the recombinant Newcastle disease virus in the preparation of a drug for treating cancer. The recombinant Newcastle disease virus provided by the present application relates to inserting a coding gene of VEGF-Trap into the genome of the recombinant Newcastle disease virus, such that the recombinant Newcastle disease virus obtained therefrom is replicated with a strong replication capability, thereby killing host cancer cells; moreover, the recombinant Newcastle disease virus has reliable safety for non-cancer cells, and shows improved anti-tumor effect and oncolytic efficiency.

The present invention provides a mesothelin binding molecule, comprising an anti-mesothelin single domain antibody. Complementarity determining regions (CDR) of the single domain antibody comprise CDR1 shown in SEQ ID NO: 1, CDR2 shown in SEQ ID NO: 2, and CDR3 shown in SEQ ID NO: 3.

The present invention provides a therapy for treating loss of GABA-mediated pre-synaptic inhibition after spinal injury. The therapeutic regimen includes spinal segment-specific upregulation of GAD65 (glutamate decarboxylase) and VGAT (vesicular GABA transporter) to modulate chronic spasticity in patients after spinal traumatic or ischemic injury.